Colby Brownlee, DO
Plastic and Reconstructive Surgery · Midland, TXNPI 1114289329
Payments from drug & device makers
Across 50 payments — averaging $35.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$532
- AbbVie$357
- Glaukos Corporation$210
- Nova Eye, Inc.$135
- Rxsight Inc$129
- Aerie Pharmaceuticals, Inc.$80
- plus $314 from 10 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$1,73299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 7 | $532 |
| AbbVie(2 entities) | 14 | $357 |
| Glaukos Corporation | 7 | $210 |
| Nova Eye, Inc. | 1 | $135 |
| Rxsight Inc | 6 | $129 |
| Aerie Pharmaceuticals, Inc. | 1 | $80 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $72 |
| Astellas Pharma US Inc | 1 | $56 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $34 |
| Sun Pharmaceutical Industries Inc. | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $28 |
| Sight Sciences, Inc. | 1 | $25 |
| Alcon | 1 | $24 |
| Amgen | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| NEW World Medical,inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENVISTA ENVY IOL$243
- enVista MX60 IOL$117
- STELLARIS$107
How this compares
$1,757 in reported general payments places this provider in the 35th percentile of 378 plastic and reconstructive surgery providers in Texas.
See all plastic and reconstructive surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 127 | $51,020 |
| LumiganBimatoprost | 77 | $31,475 |
| RocklatanNetarsudil Mesylat/Latanoprost | 69 | $31,061 |
| RhopressaNetarsudil Mesylate | 75 | $29,389 |
| Prednisolone Acetate | 1,013 | $28,981 |
| Ketorolac Tromethamine | 901 | $18,809 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $11,543 |
| Loteprednol Etabonate | 44 | $9,448 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 560 | $8,854 |
| Ciprofloxacin Hcl | 700 | $7,709 |
| Latanoprost | 1,052 | $7,513 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 42 | $7,120 |
| Brimonidine Tartrate | 206 | $6,721 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $5,024 |
| Travoprost | 30 | $3,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $80 | $60,450144 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $532 | $51,020127 claims |
| AbbVieLumigan, Combigan | $357 | $43,018107 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $34 | $9,44844 claims |
| AlconSimbrinza | $24 | $5,02422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 378 plastic and reconstructive surgery providers in Texas.
Other plastic and reconstructive surgery in Midland
- Aldona SpiegelHouston$884K
- Patrick GarveyHouston$411K
- Steven MapulaFort Worth$234K
- Charles ButlerHouston$227K
- Joshua LemmonRichardson$212K
- Michael KlebucHouston$204K
- Jeffrey FriedmanHouston$159K
- Patrick ProfferAmarillo$151K
- Rukmini RednamHouston$113K
- Edward ChangHouston$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.